JLE

Hépato-Gastro & Oncologie Digestive

MENU

Caractéristiques cliniques et bilan pré-thérapeutique des néoplasies neuroendocrines digestives Volume 26, supplément 5, Décembre 2019

  • [1] Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol 2017 ; 3 : 1335-1342.
  • [2] Scoazec J.Y., Couvelard A., Monges G. Professional practices and diagnostic issues in neuroendocrine tumour pathology : results of a prospective one-year survey among French pathologists (The PRONET Study). Neuroendocrinology. 2017;105:67-76.
  • [3] Borbath I, Bikmukhametov D, Maasberg S, et al. Assessing prognosis of neuroendocrine neoplasms: Results of a collaborative multinational effort including over 10.000 European patients - The ENETS registry. ASCO 2018 : 4095.
  • [4] Rindi G, Klimstra D, Abedi-Ardekani B, et al. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Mod Pathol 2018 ; 31 : 1770-1786.
  • [5] Heetfeld M., Chougnet C., Olsen I.H. Characteristics and treatment of patients with G3 Gastroenteropancreatic neuroendocrine neoplasms. Endocr Relat Cancer. 2015;22:657-664.
  • [6] Cadiot G, Baudin E, Coriat R, et al. Tumeurs neuro-endocrines. Thésaurus National de Cancérologie Digestive, 12-10-2017, [en ligne] http://www.tncd.org.
  • [7] Niederle MB, Pape UF, Costa F, et al. ENETS Consensus Guidelines Update for Neuroendocrine Neoplasm of the Jejunum and Ileum. Neuroendocrinology 2016 ; 103 : 125-38.
  • [8] Falconi M, Eriksson B, Kaltsas G, et al. ENETS Consensus Guidelines update for the management of functional pancreatic neuroendocrine tumors and non functional pancreatic Neuroendocrine tumors. Neuroendocrinology 2016 ; 103 : 153-71.